For sales & orders : sales@biospes.com / For techical support : tech@biospes.com
: +86-23-67567091
Recombinant SARS-Cov-2 Nucleocapsid Protein

Catalog #BRP1131
Size1 mg
Price--
In stockYes
Datasheet MSDS
Overview

Lot # Check on the product label

Size 1 mg

DescriptionRecombinant Severe Acute Respiratory Syndrome-Corona Virus-2 Nucleocapsid, SARS-CoV-2 N protein with his tag (full length).

Source E.coli

Purity >95% by SDS-PAGE

Formulation Liquid

Application Lateral flow (rapid test)Other applications have not been tested. The optimal dilutions should be determined by end user.

Storage buffer Each vial contains 0.01 M PBS (pH7.4).


Storage & Expiration
Ship at 4℃. Upon receipt, aliquot and store at -20℃ for long term.Avoid repeated freeze and thaw cycles.


Background
The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The symptoms of the virus are fever, fatigue, dry cough, and progressive dyspnea. In severe cases, the symptoms are acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulation dysfunction that can’t be corrected. The virus has been confirmed to exist the phenomenon of human-to-human transmission, the shortest incubation period of the virus is only 1 day, and the longest incubation period is 14 days. The patients in incubation period is contagious and there is no specific treatment for the disease. . After a human is infected with a new virus for the first time, the body's immune system will immune-defend the virus and produce specific antibodies. Generally, IgM antibody will appear in 1-2 weeks and IgG antibody will appear in 4 weeks.

Reference

1. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.
2. "Pneumonia diagnosis and treatment program for novel coronavirus infection" of the National Health Commission of People’s Republic of China (Trial Version 3).
3. World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance.